Full Body Radiosurgery Expands Treatment Options for Patients with Lung,
Prostate, Liver and Pancreatic Cancer
SUNNYVALE, Calif., Oct. 24 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that treatments of extracranial tumors using the CyberKnife(R) Robotic Radiosurgery System increased by 38 percent worldwide during the fiscal year ending June 30, 2008. Specifically, during this time, prostate treatment grew approximately 95 percent worldwide, while lung, liver and pancreas treatments experienced double-digit growth.
The ability of the CyberKnife System to non-invasively target tumors throughout the body with sub-millimeter accuracy is dramatically altering how the medical community and patients view radiosurgery. Designed originally for intracranial use, radiosurgery has long been an alternative to brain surgery. Building on this well established concept, Accuray extended the benefits of radiosurgery to other types of tumors, when the CyberKnife System was cleared in 2001 by the U.S. Food and Drug Administration as the first -- and only -- dedicated radiosurgery system to treat tumors anywhere in the body.
"The CyberKnife System allows us to treat a wide variety of cancer
patients -- from those who want to avoid the risks and long recovery time
associated with surgery to those who have no other options," said Irving D.
Kaplan, M.D., assistant professor, Department of Radiation Oncology at
Harvard Medical School and radiation oncologist at Beth Israel Deaconess
Medical Center in Boston, Mass. "Because it delivers high doses of
radiation with such accuracy, the CyberKnife System effectively targets
tumors while shortening tr
|SOURCE Accuray Incorporated|
Copyright©2008 PR Newswire.
All rights reserved